NCT06167603View on ClinicalTrials.gov

Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories

RecruitingOBSERVATIONAL

Enrollment

140

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

December 12, 2024

Study Completion Date

April 1, 2026

Conditions

Parkinson Disease

Interventions

DIAGNOSTIC_TEST

FDG-PET

Among other neuroimaging techniques, FDG-PET represents a unique tool to study the early metabolic alterations associated with neurodegeneration, both at the group and individual subject level.

DIAGNOSTIC_TEST

Blood test and clinical examination.

baseline, 12-months and 24 months.

Trial Locations (1)

Unknown

RECRUITING

Neurological Institute Foundation Casimiro Mondino, Pavia

All Listed Sponsors

collaborator

"IRCCS National Neurological Institute C. Mondino Foundation"

OTHER

lead

IRCCS San Raffaele

OTHER